Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers

Summary Sotera Health Company is rated Buy, leveraging a vertically integrated model and strong MOAT in global medical equipment sterilization. SHC benefits from high customer switching costs, multi-year contracts with major healthcare firms, and robust pricing power in mission-critical services. Q2 2026 results exceeded expectations, prompting raised full-year guidance; SHC trades at a discount to peers on forward EV/EBITDA despite superior margins. Litigation risk from ethylene oxide lawsuits remains the primary threat, but improving leverage and strong free cash flow support the long-term investment case. Olga Yastremska/iStock via Getty Images Summary Sotera Health Company ( SHC ), rated as a Buy, operates in the mission-critical areas of medical equipment sterilization, where the company has a global reach of over 5,000 customers. In addition to having pricing power and This article was written by Sorrento Research 131 Followers Follow I am a specialist in Asian equities after having been a sellside analyst for 13 years. In addition, I have also spent time covering US hardware and semiconductor stocks on the sellside. Within Asia, I have covered the casino, automotive, industrial, consumer and technology sectors. I have also worked on the buyside as a fund manager in long only and as an analyst in hedge funds all covering Asian equities where I have developed a keen understanding of Asian companies and economies with a focus on China. From a global equities perspective, I enjoy covering companies globally by examining key metrics such as financial statements strength, valuation upside, and conducting proper analysis of the competitive advantages of the company. Throughout my career, I have found and written on undiscovered small cap companies which have increased in equity value by multiple times. I would like to write for Seeking Alpha where my goal is to help investors cut through the noise and to focus on fundamentals and the company’s competitive outlook instead of the momentum trade. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.